IQVIA Raises 2026 Outlook As Clinical Bookings Climb 15% To $3.2 Billion

The research-services company also trimmed its backlog estimate by about $2.1 billion and set a December 1 Investor Day.

Share
IQVIA Raises 2026 Outlook As Clinical Bookings Climb 15% To $3.2 Billion

IQVIA, which runs clinical trials and sells healthcare data to drugmakers, raised its full-year 2026 guidance for revenue, adjusted EBITDA and adjusted earnings per share after posting third-quarter revenue of $4,428 million, up 8.0% as reported, the company said Tuesday in an 8-K filing. Chairman and CEO Ari Bousbib said revenue, adjusted EBITDA and adjusted diluted EPS all topped the high end of the company's own expectations.

Revenue, profit and the new guidance

Revenue grew 8.6% at constant currency. Net income was $350 million, or $2.10 a share. On an adjusted basis, EBITDA reached $1,032 million, up 8.7%, and earnings per share were $3.34, up 11.3% from a year earlier.

The new 2026 outlook calls for revenue of $17,350 million to $17,500 million, adjusted EBITDA of $4,025 million to $4,055 million and adjusted earnings per share of $12.90 to $13.00. The revenue range includes 250 basis points (2.5 percentage points) of contribution from acquisitions, including some the company expects to complete by year-end, plus roughly 20 basis points of currency tailwind.

Free cash flow was $667 million, which the company said was 120% of adjusted net income. Net debt stood at $13,818 million at September 30, or 3.45 times trailing twelve-month adjusted EBITDA.

Bookings and a smaller backlog

Net new bookings in the Research & Development Solutions segment were $3.2 billion, up 15%, for a book-to-bill ratio of 1.2x. Over the last twelve months, bookings were $11.7 billion, up 14%. Bousbib called it the company's strongest clinical quarterly bookings since 2022.

Segment revenue rose 8.7% to $2,639 million in R&D Solutions and 6.9% to $1,789 million in Commercial Solutions. Bousbib also pointed to more than 400 AI agents deployed to date.

A review of inactive trials cut the backlog estimate by about $2.1 billion, leaving R&D Solutions contracted backlog at $32.6 billion. The company said the change does not affect historical results, 2026 guidance, book-to-bill or next-twelve-month revenue from backlog. It expects about $9.4 billion of the backlog to turn into revenue over the next twelve months, growth of 10% year over year.

Reorganized segments and Investor Day

IQVIA has reported in two segments since January 1, 2026, with prior periods recast. The company, which has been described in its annual report as serving life-sciences clients in over 100 countries, runs trials, sells data and software, and supplies contract sales teams.

Management will present at an Investor Day on Tuesday, December 1, starting at 9:00 a.m. ET.

Management's Investor Day presentations on December 1 are slated to run until about 12:30 p.m. ET.

Sources

More on IQVIA Holdings

All IQVIA Holdings (IQV) coverage →